Objective: Although joint symptoms are commonly reported after menopause, observational studies examining exogenous estrogen's influence on joint symptoms provide mixed results. Against this background, estrogen-alone effects on joint symptoms were examined in post hoc analyses in the Women's Health Initiative randomized, placebo-controlled, clinical trial.
A lthough joint symptoms are commonly reported by women after menopause, 1,2 a determinant role for estrogen during menopause has not been established. 3, 4 Although some observational studies examining relationships between exogenous estrogen use and joint symptoms report a favorable effect, 2,5<8 negative studies have been reported, 9<12 and no clear association has emerged. 3, 13 Hormonal influence on joint symptoms was examined previously in the Women's Health Initiative (WHI) trial evaluating estrogen-alone use in women who have had hysterectomy, where analyses compared women with no joint pain with women with moderate or severe pain. At 1 year, a marginal effect of estrogen alone, compared with placebo, on joint pain was seen (P G 0.04). In analyses conducted on adherent women at the end of the intervention, about 5% more women in the estrogen group were free of joint pain (P = 0.001). 14 The current analyses in this WHI trial expand those observations. Joint symptoms are now evaluated for severity and serially assessed along with joint swelling frequency and severity. The findings are presented for women assigned to estrogen alone and compared with those assigned to placebo at baseline and after 1 year (all participants) and after 3 and 6 years (in a 9.9% randomly identified subset with joint symptom assessments) in both intent-to-treat analyses and adherence-adjusted analyses.
The study objective was to determine whether estrogenalone use favorably influences the incidence or severity of joint pain or joint swelling in postmenopausal women. The WHI randomized, placebo-controlled, clinical trial evaluating estrogen-alone use in postmenopausal women who have had hysterectomy provides an opportunity for evaluating this association in a rigorous manner.
METHODS WHI estrogen-alone trial
The study design and conduct of the WHI trial evaluating estrogen alone have been reported elsewhere. 15, 16 Postmenopausal women aged between 50 and 79 years who have had hysterectomy with a life expectancy of 3 years or longer and had no prior breast cancer were entered into the randomized, double-blind, placebo-controlled trial at 40 US clinical centers. Women using hormones at baseline required a 3-month washout period before study entry.
A total of 10,739 postmenopausal women were randomized, using a permuted/blocked algorithm, to receive daily oral conjugated equine estrogens (0.625 mg/d) or matching placebo. The influence of estrogen alone on primary disease outcomes has been reported. 15<18 Women participating in the estrogen-alone trial were invited to join an additional randomized, placebo-controlled trial evaluating daily calcium (1,000 mg) plus vitamin D (400 IU) supplementation at their first or second annual follow-up visit. The influence of calcium plus vitamin D supplementation on major primary study endpoints has also been previously reported. 19<21 The influence of estrogen alone on joint symptoms is the focus of the current report.
The WHI estrogen-alone clinical trial obtained institutional review board approval from all participating institutions, and a written informed consent form was obtained from all participants. Statistical analyses and data management were conducted at the WHI clinical coordinating center.
Data collection
At entry, information on demographics, family and medical history, and lifestyle factors was obtained by self-reported questionnaires. Medication and supplement use was assessed by interviewer-administered questionnaire. A written protocol, central training of clinic staff, and quality assurance visits by the WHI clinical coordinating center ensured uniform data collection across centers.
Physical activity was assessed by questionnaire, with the information used to generate metabolic equivalents. 22 Measurements of height and weight were performed by clinical personnel to determine body mass index (BMI). Total daily calcium intake and total daily vitamin D intake were defined as the sum of dietary intake (assessed with a modified Block Food Frequency Questionnaire) 23 and self-reported intake from supplement and prescription medication.
Joint symptoms in all participants were assessed by questionnaire at entry into the trial and at the first annual visit. In addition, joint symptoms were assessed in a 9.9% random subsample of participants on years 3 and 6 after entry in the estrogen-alone randomized clinical trial. Sampling was carried out on the entire clinical trial population (n = 68,132), with a sixfold higher odds at selection for non-white participants. Joint pain and joint symptoms were assessed separately and categorized by presence (yes, no) and severity (mild, moderate, severe) among those with each symptom. The joint pain and joint swelling severity scores were calculated as mean (0, none; 1, mild; 2, moderate; 3, severe).
Information on other clinical outcomes was collected at annual clinic visits and semiannual contacts. Annual clinic visits included counting or weighing returned pills as an adherence measure.
Women entered the study between 1993 and 1998. The estrogen-alone and placebo interventions ended on February 29, 2004, after a mean follow-up of 7.1 years. Thus, all presented data through year 3 and almost all data through year 6 reflect findings during active intervention. Of the 10,739 estrogen-alone trial participants, 6,176 were randomized into the calcium and vitamin D supplementation trial, receiving either calcium carbonate (1,000 mg as elemental calcium) with vitamin D 3 (400 IU) or matching placebo daily.
Statistical analysis
Analyses of joint symptoms used all available data at each time point. The frequency and severity of joint symptoms (pain and swelling) were compared by randomization group assignment (active vs placebo). A logistic regression model was used to compare the frequency of having any symptoms with the frequency of having no symptoms in analyses both unadjusted and adjusted for age and race/ethnicity. Similarly, the average symptom score where a response of Bnone[ equals 0 and a response of Bsevere[ equals 3 was compared in unadjusted and adjusted linear regression models incorporating age, BMI, and WHI calcium and vitamin D supplementation trial participation. Score differences between baseline and follow-up were computed the same way. To help place the joint score differences in clinical context, regression models examined the year-to-year changes in joint pain and joint swelling in the placebo group.
Sensitivity analyses examined estrogen's influence on participants who were adherent to study medication use by censoring follow-up 6 months after a participant became nonadherent. Nonadherence was defined as using less than 80% of study pills or initiating nonprotocol hormone therapy.
All analyses were carried out with SAS version 9.1.3.
All P values are two-sided. P values of 0.05 or less were considered significant. The WHI study is registered with ClinicalTrials.gov (NCT000000611).
RESULTS
Most baseline clinical and demographic characteristicsV including age, BMI, nonsteroidal anti-inflammatory drug use, physical activity, self-reported history of rheumatoid arthritis, and previous hormonal exposureVwere comparable in the two randomization groups. In addition, total calcium and vitamin D intakes at baseline, reflecting both dietary intake and supplement use, were similar in the two randomization groups. Finally, participation in the WHI calcium and vitamin D supplementation trial was also balanced between the randomization groups (Table 1) , with the latter being relevant to the year 3 and year 6 results.
By the termination of study drug intervention after a mean follow-up of 7.1 years, 53.8% of participants had stopped study drugs, with similar frequencies noted between randomization groups. In addition, 5.7% of the estrogen-alone group and 9.1% of the placebo group had started hormone therapy outside the trial. 15 Joint pain and joint swelling at entry into the estrogen-alone trial were closely comparable in the two randomization groups, with about 77% of participants reporting some joint pain and about 40% of participants reporting joint swelling. After 1 year, women randomized to estrogen alone, versus placebo, had joint pain significantly less frequently (76.3% vs 79.2%, respectively, P = 0.001) and had significantly lower mean (SD) joint pain scores (1.16 [0.87] vs 1.22 [0.88], P G 0.001). In contrast, joint swelling frequency was higher in the estrogen-alone group (42.1% vs 39.7%, P = 0.02), as was swelling severity score (0.58 vs 0.52, P G 0.001).
Serial analyses of joint symptoms also found differences between randomization groups. On year 3 in the subset of participants with joint symptom assessment, women randomized to estrogen continued to have joint pain less frequently compared with women randomized to placebo (74.2% vs 79.8%, P = 0.03). In addition, women in the estrogen-alone group had no change in mean (SD) pain score from baseline (0.01 [0.81]), whereas those in the placebo group had a mean Participants were excluded if they became nonadherent (using G80% of study pills or initiating nonprotocol hormone therapy) before the follow-up visit.
CEE, conjugated equine estrogens.
(SD) increase in pain score (0.15 [0.94], P = 0.01). Similar findings for joint pain continued through year 6 but did not achieve statistical significance. Joint swelling continued to be significantly higher through year 6 in the estrogen group (P = 0.04), whereas change in the joint swelling severity score from baseline was no longer statistically significant (P = 0.31; Table 2 ). To put into clinical context the joint pain score and joint swelling score differences in the estrogen group compared with the placebo group at 1 year (0.06 and 0.08, respectively), we used regression models to assess year-to-year changes in these parameters in the placebo group. The mean joint pain score increased by 0.0003 with a 1-year increase in age, and the mean joint swelling score decreased by 0.001 with a 1-year increase in age.
The influence of adherence on joint symptom findings was examined by censoring joint symptoms reported 6 months after the participants first became nonadherent (took G80% of study drugs or started nonstudy hormone therapy). A stronger association between estrogen use and lower frequency of joint pain was seen, especially for findings after 1 year and 3 years of follow-up. On year 3, 72.5% of adherent women randomized to estrogen alone had joint pain compared with 81.7% of adherent women randomized to placebo (P = 0.006; Table 3 ). In contrast to joint pain where adherence-adjusted analyses provided a stronger incidence of the favorable influence of estrogen alone, adherence-adjusted analyses attenuated estrogen effect on joint swelling. On year 3, the difference in joint swelling between the estrogen-alone group and the placebo group adherent participants was no longer statistically significant (P = 0.31; Table 3 ). Analyses of both joint pain and joint swelling on year 6 were hindered by a limited number of adherent participants.
DISCUSSION
In the present post hoc analyses in a randomized clinical trial setting, statistically significantly fewer women in the estrogen-alone group compared with the placebo group had joint pain after 1 year and 3 years. In adherence-adjusted analyses, stronger favorable associations with estrogen use and reduced joint pain are seen. Thus, in a randomized clinical trial, estrogen-alone use in postmenopausal women results in a modest but sustained and statistically significant reduction in joint pain. In contrast, joint swelling was more common in estrogen-alone group participants, but the findings were attenuated in adherence-adjusted analyses.
The current report expands on prior findings in this trial 14 by including information on joint pain severity, joint swelling, and joint symptom severity, and by adding serial and adherence analyses. The statistically significant reduction in joint pain frequency in intention-to-treat analyses after 1 year on the study in the estrogen-alone group included all participants, whereas prior analyses excluded women with mild joint pain. 14 In our review, no other randomized trial has described the influence of estrogen alone on joint symptoms. Although the reduction in joint pain score with estrogen-alone use was modest, it far exceeded the year-to-year increase in joint pain score seen in placebo group participants.
The apparent opposite effects of estrogen alone on joint pain (decrease) and joint swelling (increase) seem contradictory but may be related to the performance of the self-reported joint symptom measures. Self-reported joint pain has reasonable correlation with clinical and radiographic osteoarthritis measures. 24, 25 However, the relation between self-reported joint swelling and articular change has been questioned. 26 Importantly, adherence-adjusted analyses strengthened the association of estrogen alone with reduced joint pain but attenuated its association with increased joint swelling.
Supportive findings for a favorable influence of estrogenalone use on joint pain come from other prior analyses in this WHI randomized trial. 27, 28 Women who have had a hysterectomy and were randomized to estrogen alone had fewer cases of rheumatoid arthritis (25/5,076 vs 37/5,195 cases for estrogen alone vs placebo, respectively), but the difference was not statistically significant (hazard ratio, 0.69; 95% CI, 0.41-1.14; P = 0.149). 27 Estrogen-alone users in the trial were also found to have significantly fewer hip and knee joint replacements (222/5,076 vs 269/5,195 cases for estrogen alone vs placebo, respectively; hazard ratio, 0.84; 95% CI, 0.70-1.00; P = 0.05). 28 Given that arthroplasty due to osteoarthritis is generally indicated when pain can no longer be managed with pain medications, the findings support an association between estrogen-alone use and a lower frequency of joint symptoms.
In contrast to the findings in the WHI estrogen-alone trial, in the WHI estrogen plus progestin trial on women with an intact uterus, there was no association between combined hormone therapy use and arthroplasty frequency. 28 This difference between the two WHI hormone trials reinforces the message that current findings are based on one regimen (conjugated equine estrogens 0.625 mg/d) alone in women who have had hysterectomy, and the results cannot be extrapolated to other hormone regimens or treatment durations.
Biological plausibility for an association between estrogen and joint pain is provided by clinical studies of estradiol and its metabolites and osteoarthritis risk. In a study of 842 premenopausal and perimenopausal women, women with radiographically defined osteoarthritis had estradiol concentrations in the lowest tertile (odds ratio, 1.88; 95% CI, 1.07-3.51) compared with women without osteoarthritis. 29 More recently, significantly lower free estradiol levels were seen in both premenopausal and postmenopausal women with osteoarthritis compared with levels in healthy women. 30 Findings from observational studies examining relationships among joint problems (including arthritis) and menopausal hormone therapy have been mixed, and their heterogeneity with respect to outcome measures and study populations has precluded pooling. 3 In a recent review, although insufficient information supporting strong conclusions was acknowledged, evidence was nonetheless supportive of an effect of endogenous and exogenous estrogen on joint health. 31 Although further study is warranted, the current results, seen in a randomized clinical trial setting, support a moderate effect of exogenous estrogen on mitigating joint pain. Any consideration of estrogen use for this purpose must incorporate available information on the identified risks and benefits of menopausal hormone therapy, including the admonition to use the lowest dose for the shortest duration, consistent with the intended therapeutic goal. 15, 16 Likely mechanisms mediating estrogen's influence on joint pain include reduction in inflammation markers and reduction in cartilage turnover as potential contributors to arthritis risk 32, 33 in both preclinical 34 and clinical 35, 36 settings. In addition, if future studies could confirm associations among cartilage turnover, joint pain, and estrogen levels, a clinical model for more rapidly identifying potential intervention strategies for joint problems could result. Finally, both preclinical and clinical studies suggest that estrogens may modulate pain processing pathways. 1 The current findings are of utmost relevance to women with limiting climacteric symptoms near the beginning of menopause who have had hysterectomy and are considering estrogen-alone use. Recent follow-up 16, 18 and subgroup analyses 37 from this WHI randomized trial evaluating estrogen alone indicate a favorable benefit/risk balance for estrogen use for about 5 years. 16 A modest and favorable effect on joint symptoms represents one additional factor for women contemplating estrogen-alone use in this setting.
These findings also inform on aromatase inhibitorYassociated joint symptoms. Aromatase inhibitors substantially lower circulatory estrogen levels 38 and increase arthralgias. 39<41 Exogenous estrogen's reduction of joint pain frequency supports the concept that such arthralgias, at least in part, may be influenced by circulatory estrogen levels. Given the uncertainty regarding the potential influence of exogenous hormones on breast cancer recurrence, 42, 43 estrogen alone should not be used to treat joint symptoms arising from aromatase inhibitor use in women with resected breast cancer.
Study strengths include the large, well-characterized, ethnically diverse study population and serial joint symptom determination within the context of a randomized clinical trial, using a quantitative instrument that was prospectively applied. However, joint symptoms were not primary study endpoints, and the findings emerged from post hoc analyses. In addition, the joint pain and joint swelling scales used have not been compared with other instruments or formally validated.
CONCLUSIONS
Current study findings suggest that estrogen-alone use in postmenopausal women who have had a hysterectomy results in a modest but sustained and statistically significant reduction in joint pain.
